Asthma: comparative bronchodilator effects of ipratropium bromide and isoproterenol.
The effect of ipratropium bromide administered at two dosage levels, 40 and 80 mug, isoproterenol, 150 mug, and placebo using a metered dose inhaler was evaluated in ten adult patients with asthma in a double-blind, crossover study. The new atropine-like drug proved to be as effective a bronchodilator as isoproterenol in this study, although it had a later peak effect. Ipratropium bromide had a longer course of action than isoproterenol (4 hours compared to 1-2 hours) and was free of significant side effects. The larger dose of the new drug produced a slightly greater and longer-acting effect than the smaller dose. Ipratropium bromide seems to have had bronchodilator effects on both large and small airways.
D000328:Adult; D000403:Airway Resistance; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001286:Atropine Derivatives; D002986:Clinical Trials as Topic; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D009241:Ipratropium / Q000627:therapeutic use*; D007545:Isoproterenol / Q000627:therapeutic use*; D008297:Male; D008449:Maximal Expiratory Flow-Volume Curves; D008450:Maximal Midexpiratory Flow Rate; D008875:Middle Aged; D013997:Time Factors
D001286:Atropine Derivatives; D009241:Ipratropium; D007545:Isoproterenol